What this study adds?
- PK
of dapagliflozin in patients with T1DM was characterized employing a
population PK approach using phase 2 and phase 3 clinical data
- None of the identified covariates affected systemic dapagliflozin
exposure to a clinically relevant extent
- Systemic exposure of dapagliflozin was comparable in patients with
T1DM and T2DM